BMRN : Analysis & Opinions

  1. Soros 13F Points to More Than Just Emerging Markets

    November 15, 2016
    Soros Fund Management's 13F for Q3 indicates new positions in several energy comapnies, call options for Bank of America, ...
  2. BioMarin Takes Aim at Rival Sarepta (BMRN, SRPT)

    September 26, 2016
    Following its loss in a U.S. patent infringement ruling, BioMarin is taking further steps agains rival Sarepta
  3. Chardan Analyst: Amicus Therapeutics Could Be Bought For $22.5 ...

    April 12, 2016
    Shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD) climbed 7 percent in the pre-market hours after a Wall Street analyst ...
  4. The Top 5 Large Cap Biotechnology Stocks for 2016 (AMGN, BIIB)

    January 5, 2016
    Discover the top five biotechnology stocks for 2016. Learn each company's main revenue drivers and what factors cause their ...
  5. Sarepta Gets FDA Green Light to Submit Application (SRPT, BMRN)

    May 20, 2015
    It's not often you see a biotech soar more than 60% after announcing plans to submit a marketing application to the Food ...
  6. The Biggest Biotech Companies

    January 15, 2015
    These biotech firms want to revolutionize medicine. If successful, they may see high profits, but investing in these companies ...
Trading Center